- Home
- NMS vs NRXP Comparison
NMS vs NRXP Comparison
Compare NMS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | NRXP |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMS | NRXP |
|---|---|---|
| Price | $12.12 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 17.4K | ★ 523.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.07 | $1.58 |
| 52 Week High | $12.43 | $3.84 |
Technical Indicators
Market Signals| Indicator | NMS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 40.83 |
| Support Level | $12.01 | $1.65 |
| Resistance Level | $12.22 | $1.99 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.75 | 11.32 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.